Article
Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
Antimicrobial agents and chemotherapy - 1 Sept 2015
Shields Ryan K, Clancy Cornelius J, Hao Binghua, Chen Liang, Press Ellen G, Iovine Nicole M, Kreiswirth Barry N, Nguyen M Hong
Abstract excerpt
Avibactam is a novel β-lactamase inhibitor with affinity for Klebsiella pneumoniae carbapenemases (KPCs). In combination with ceftazidime, the agent demonstrates activity against KPC-producing K. pneumoniae (KPC-Kp). KPC-Kp strains are genetically diverse and harbor multiple resistance determinants, including defects in outer membrane proteins and extended-spectrum β-lactamases (ESBLs). Mutations in porin gene...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.